fruitpunch
Member
Can someone pls explain how monoclonal antibody therapy works .
gene therapy (1 Viewer)
- Thread starter fruitpunch
- Start date
Eagle Mum
Well-Known Member
- Joined
- Nov 9, 2020
- Messages
- 561
- Gender
- Female
- HSC
- N/A
Only have time for a brief reply but might help to point you in the right direction:
- Monoclonal antibody therapy isn’t gene therapy (noting your post vs title of thread).
- They are synthesised but the way they act is the same as the antibodies our bodies produce.
- Each mAb targets a specific antigen in our body, usually a receptor or other protein on the surface of particular cell type(s).
- Their action is either to activate or inactivate (depends on the target protein and/or mAb) a specific function of, or process in, that particular cell type.
- The most common designs are mAbs that inactivate growth signals of cancer cells or initiate processes that lead to death (apoptosis) of the cancer cell.
- mAbs are not exclusively designed for cancer treatment, but that’s the most popular application (https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808)
- other applications of mAb therapy include blocking protein signals that enhance inflammation (ie. mAbs act as anti-inflammatory agents in autoimmune conditions): https://www.intechopen.com/chapters/54286
- Since their targets and therefore actions are specific, they tend to have fewer side effects compared to other/older treatments and are therefore an attractive field for creating new therapies.
- Monoclonal antibody therapy isn’t gene therapy (noting your post vs title of thread).
- They are synthesised but the way they act is the same as the antibodies our bodies produce.
- Each mAb targets a specific antigen in our body, usually a receptor or other protein on the surface of particular cell type(s).
- Their action is either to activate or inactivate (depends on the target protein and/or mAb) a specific function of, or process in, that particular cell type.
- The most common designs are mAbs that inactivate growth signals of cancer cells or initiate processes that lead to death (apoptosis) of the cancer cell.
- mAbs are not exclusively designed for cancer treatment, but that’s the most popular application (https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808)
- other applications of mAb therapy include blocking protein signals that enhance inflammation (ie. mAbs act as anti-inflammatory agents in autoimmune conditions): https://www.intechopen.com/chapters/54286
- Since their targets and therefore actions are specific, they tend to have fewer side effects compared to other/older treatments and are therefore an attractive field for creating new therapies.
Last edited: